Daily News

Future Journey of Transcatheter Mitral Valve Interventions

April 24th Hot Topics Session of TCTAP 2021 Virtual

Read More
<Daewoong Co., Ltd.

Antithrombotics after TAVR: seeking an optimal strategy in an unsolved game

April 24th Hot Topics Session of TCTAP 2021 Virtual

Read More

Antithrombotic Therapy in East Asian with ACS/PCI: Updated Evidences for East-Asian Paradox

April 23th Hot Topics Session of TCTAP 2021 Virtual

Read More

A New Radiation Protocol to Reduce Radiation for Complex PCI

April 23th Hot Topics Session of TCTAP 2021 Virtual

Read More
<B.Braun Korea, Ltd., Co.

Antithrombotic Therapy after CTO-PCI: A Long Way to Go

April 23th Hot Topics Session of TCTAP 2021 Virtual

Read More

Left Main PCI vs CABG: From the Final EXCEL Outcomes to Patient Recommendations

April 23th Hot Topics Session of TCTAP 2021 Virtual

Read More

Angiography-derived Coronary Physiology

April 23th Hot Topic Session of TCTAP 2021 Virtual

Read More
<Cardinal Health Korea Ltd.

Vulnerable plaques: What you can predict, you can prevent

April 22th Hot Debates 2021 in Interventional Cardiology of TCTAP 2021 Virtual

Read More

TAVR & Antithrombotics Debates

April 22th Hot Debates 2021 in Interventional Cardiology of TCTAP 2021 Virtual

Read More

Ideal Revascularization for Left Main: Still No Definitive Winner or Loser

Two leading figures in unprotected left main coronary artery (ULMCA) disease engaged in a “Hot Debate” over the merits of surgical versus percutaneous revascularization.in left main at TCTAP 2021 Virtual that kicked off online April 21.

Read More
<Shanghai MicroPort Medical (Group) Co., Ltd.

Transcatheter Mitral Valve Repair: Guideline Changes, Evidence Gaps and Future Directions

April 22th Plenary Session of TCTAP 2021 Virtual

Read More

The Long TAVR Journey: Chain of RCTs, Guideline Changes, and Future Directions

Martin Bert Leon, MD (Columbia University Medical Center/New York-Presbyterian Hospital, New York, USA) presented a special keynote lecture on the TAVR revolution and TAVR clinical evidence accumulated through decades during a plenary session at TCTAP 2021.

Read More

Plenary Session of TCTAP 2021: Special Keynote Lectures Part-I: Coronary and Antithrombotics

Updates on antithrombotic therapy for post-PCI ACS based on latest data

Read More

The Future of PCI: Indication, Technology, Outlook

Percutaneous coronary intervention (PCI) has gained incredible traction over the years - and leading cardiologists during a special keynote lecture at TCTAP 2021 Virtual on April 21 expounded in detail the direction of its promising future.

Read More

Atherosclerotic Plaque Progression and Imaging

The 11th winner of TCTAP award “Master of the Masters”

Read More

How Should Antithrombotic Strategies for CHIP and HBR Patients be tailored

Philip M. Urban, MD (Hopital de la Tour, Switzerland) addressed the prevalence of high bleeding risk (HBR) in patients of percutaneous coronary intervention (PCI) registries across multiple geographical regions at a session held during TCTAP 2021 Virtual.

Read More

iFR vs. FFR in Severe AS Patients: Which Is Better, and Is It Valid?

April 21th TCTAP Workshop Session of TCTAP 2021 Virtual

Read More

Percutaneous Treatment Considerations for Functional Mitral Regurgitation

Samir R. Kapadia, MD (Cleveland Clinic, Ohio, USA) discussed functional mitral regurgitation (MR) treatment considerations while sharing his experience with MitraClip Implant during a session at TCTAP 2021 Virtual that ran from April 21 to 24.

Read More

Chaos in Procedural MI (PMI) Definitions in PCI vs CABG Trials: How to Reconcile?

Patrick W. Serruys (NUI Galway, Ireland), examined the unresolved chaos regarding procedural MI (PMI) definition in PCI vs CABG trials during a session at TCTAP 2021 Virtual, suggesting possible upheaval of PMI definitions altogether.

Read More